Clinical Trials Sponsored by Vaxart

Total 37 results

Vaxart

Active, not recruiting

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Norovirus Infections

United States
Vaxart

Completed

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)

Norovirus Infections

United States
Vaxart

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Condyloma

Argentina, Chile, Ecuador, Serbia
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
Vaxart

Completed

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Seasonal Influenza Preventative Vaccine Pharmacodynamics

United States
Vaxart

Completed

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Norovirus Gastroenteritis

United States
Vaxart

Completed

Safety Study of an Oral Vaccine to Prevent Avian Influenza (H5N1)

Avian Influenza | Bird Flu

United States
Vaxart

Completed

Norovirus Challenge Study (G1-1 Challenge)

Norovirus Infections

United States
Vaxart

Completed

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

Covid19

United States
Vaxart

Completed

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers ((VXA-G1-1-NN))

Norovirus Infections

United States
Vaxart

Completed

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)

Norovirus Infections

United States
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Vaxart

Completed

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

COVID-19

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Vaxart

Withdrawn

A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Rhinovirus | Upper Respiratory Tract Infection
Vaxart

Completed

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Influenza

United States
Vaxart

Completed

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum (ICC H1)

Seasonal Influenza

United States
Vaxart

Completed

Immunogenicity of ND1.1 by Delivery Directly to the Ileum (ICC H5)

Avian Influenza

United States
Anaconda Pharma

Completed

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Human Papillomavirus Infection | Condylomata Acuminata | Anogenital Warts

Argentina, France
Aviragen Therapeutics

Completed

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

Healthy

United States
WCCT Global
Vaxart

Completed

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

Norovirus Infection

United States
Biota Pharmaceuticals, Inc.

Completed

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics

United States
Biota Pharmaceuticals, Inc.

Completed

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (SPIRITUS)

Asthma

United States, Bulgaria, Czechia, Georgia, Poland, Romania
Biota Pharmaceuticals, Inc.

Completed

Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics

United States
Biota Pharmaceuticals, Inc.

Completed

A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers

Healthy

United States
Biota Pharma Europe Limited

Completed

Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study

Respiratory Syncytial Virus (RSV) Infection

United Kingdom
Biota Scientific Management Pty Ltd

Completed

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (RHINO)

Rhinovirus

United States
Biota Scientific Management Pty Ltd

Completed

Safety Study of Oral BTA9881 to Treat RSV Infection

Respiratory Syncytial Virus Infections

Australia
Biota Scientific Management Pty Ltd

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

Drug-Drug Interaction Healthy Volunteers

United States
Vaxart
Biomedical Advanced Research and Development Authority

Completed

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Influenza

United States
Biota Scientific Management Pty Ltd
Department of Health and Human Services

Terminated

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (FROSTY)

Influenza

United States
Biota Scientific Management Pty Ltd
Department of Health and Human Services

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma

Asthma

United Kingdom
Biota Scientific Management Pty Ltd
Department of Health and Human Services

Completed

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza (Igloo)

Influenza

United States, Peru, Hungary, Canada, South Africa, Estonia, Australia, Belgium, Bulgaria, Colombia, France, Germany, Latvia, Mexico, New Zealand, United Kingdom
Biota Scientific Management Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

CS-8958 Single Inhaled Dose in Elderly

Influenza

United Kingdom
Biota Scientific Management Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958

Influenza

United Kingdom
Biota Scientific Management Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958

Influenza

United Kingdom

3

Subscribe